Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass
NCT07212842 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124
Last updated 2025-10-08
Summary
Introduction: Fluid overload and systemic inflammation are major contributors to postoperative complications in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). Objective: To evaluate the effects of blood washing with methylene blue during zero-balance ultrafiltration (ZBUF) on fluid overload and systemic inflammatory response. Methodology: Fluid status was assessed using the InBody S10 precision bioimpedance device, measuring extracellular water (ECW), total body water (TBW), intracellular water (ICW), and the ECW/TBW ratio. Pulmonary congestion and intravascular volume were evaluated separately using a Philips Lumify S4-1 transducer with a Samsung tablet. Pulmonary congestion was confirmed by the presence of B-lines on lung ultrasound. Intravascular volume was assessed via the inferior vena cava (IVC) distensibility index (DI) during mechanical ventilation and collapsibility index (CI) during spontaneous breathing. Inflammatory cytokine levels were measured using a Luminex xMAP-based multiplex immunoassay.
Conditions
- Cardiopulmonary Bypass Surgery
- Aortic Valve Surgery
- Mitral Valve Surgery
- Myocardial Revascularization Surgery With Extracorporeal Circulation
Interventions
- DRUG
-
Methylene Blue
This protocol was designed to perform intraoperative blood lavage with methylene blue at the end of surgery, with a duration of 20 minutes. A low dose of 1 mg/kg of body weight was administered. The objective was not to elicit hemodynamic effects, which require higher doses, but rather to exploit the anti-inflammatory and antioxidant properties of methylene blue. Methylene blue was diluted in 1000 mL of 0.9% saline. An equivalent volume of fluid was removed simultaneously by zero-balance ultrafiltration, maintaining a fluid-equilibrium state throughout the 20-minute procedure. For this purpose, a dedicated circuit was developed to enable concurrent blood lavage and ultrafiltration. Blood was withdrawn through a dedicated port integrated into the SORIN oxygenator and directed by a centrifugal pump to a small reservoir containing the methylene blue solution. From this reservoir, the blood passed through a hemoc
- PROCEDURE
-
Conventional ultrafiltration
Conventional ultrafiltration (CUF). CUF during cardiopulmonary bypass (CPB) is performed to remove excess fluid and solutes from the patient's blood during cardiac surgery, thereby limiting fluid accumulation and attenuating pro-inflammatory effects. This technique increases hematocrit, improves cardiopulmonary function, and reduces the need for blood transfusions. Unlike modified ultrafiltration (MUF), which is performed after weaning from CPB, CUF is carried out simultaneously with CPB while the heart-lung machine remains in operation.
- PROCEDURE
-
Zero-balance ultrafiltration
Zero-balance ultrafiltration (Z-BUF). Z-BUF is performed during cardiopulmonary bypass (CPB) to maintain fluid equilibrium by removing plasma water and solutes while simultaneously infusing an equal volume of replacement fluid, thereby achieving a net zero fluid balance. This technique has been shown to decrease urine output, reduce tissue edema and the inflammatory response, improve arterial oxygenation (PaO₂), and lower the need for postoperative blood transfusions.
Sponsors & Collaborators
-
University of Sao Paulo
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-12
- Primary Completion
- 2023-08-25
- Completion
- 2024-03-16
Countries
- Brazil
Study Locations
More Related Trials
-
A Comparison Between 5% Albumin and 6% Hydroxyethyl Starch 130/0.4 in Priming Solution for Cardiopulmonary Bypass and Post-bypass Maintenance Fluid in High-risk Patients
NCT01644084 ·Status: COMPLETED ·Phase: NA
-
Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
NCT04296071 ·Status: RECRUITING
-
Modified Ultrafiltration in Cardiac Surgery
NCT00998647 ·Status: COMPLETED
-
Conventional Ultrafiltration Versus Dilutional Ultrafiltration in Pediatric CPB Patients
NCT07221630 ·Status: NOT_YET_RECRUITING
-
Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution
NCT03326323 ·Status: COMPLETED
-
Quantification of Thrombocytes Number and Function in Patients Undergoing Prolonged Extracorporeal Circulation
NCT02771223 ·Status: UNKNOWN
-
The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass
NCT01435304 ·Status: COMPLETED ·Phase: NA
-
Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery
NCT03446599 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effects of Cardiopulmonary Bypass (CPB)-Leukocyte Filtration on Interleukins Serum Levels and Pulmonary Function
NCT01469676 ·Status: COMPLETED ·Phase: NA
-
Cardiopulmonary Bypass (CPB) Pumps and Blood Activation
NCT00187967 ·Status: UNKNOWN ·Phase: NA
-
Light Therapy in Cardiopulmonary Bypass Surgery
NCT02928887 ·Status: WITHDRAWN ·Phase: NA
-
Processed Residual Pump Blood in Cardiac Surgery: The PRBC Trial
NCT01173822 ·Status: COMPLETED ·Phase: NA
-
Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass
NCT03204357 ·Status: RECRUITING ·Phase: NA
-
Optimizing Pulsatility During Cardiopulmonary Bypass
NCT05344573 ·Status: RECRUITING
-
Plasma Angiopoietin Levels in Children Following Cardiopulmonary Bypass
NCT01489475 ·Status: COMPLETED
-
Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass
NCT01072747 ·Status: UNKNOWN ·Phase: PHASE3
-
Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
NCT02405195 ·Status: COMPLETED
-
Cardioprotective Effects of Endogenous Erythropoietin in Patients Undergoing Coronary Artery Bypass Surgery
NCT00854217 ·Status: COMPLETED ·Phase: NA
-
Prolonged Cardiopulmonary Bypass Time as Predictive Factor for in Hospital Infection
NCT04548167 ·Status: COMPLETED
-
Clinical Trial Comparing Heparin and Protamine Fixed and Titrated Doses in Cardiac Surgery With Cardiopulmonary Bypass
NCT01267487 ·Status: COMPLETED ·Phase: PHASE4
-
Intermittent Normoxia Reduces Myocardial Reperfusion Injury
NCT01348906 ·Status: UNKNOWN ·Phase: NA
-
Hemadsorption During and After Cardiopulmonary Bypass to Modulate the Inflammatory Response
NCT04157647 ·Status: UNKNOWN ·Phase: NA
-
Postoperative Use Of Pump Blood İn Cardiopulmonary Bypass Surgery
NCT06824753 ·Status: COMPLETED ·Phase: NA
-
Intra-aortic Balloon Counterpulsation in Patients Undergoing Cardiac Surgery
NCT02143544 ·Status: UNKNOWN ·Phase: NA
-
Use of Bicarbonate to Reduce the Incidence of Acute Renal Failure After Cardiac Surgery
NCT00484354 ·Status: COMPLETED ·Phase: PHASE2